Subscribe: MedWorm: Liposarcoma
http://www.medworm.com/rss/medicalfeeds/cancers/Liposarcoma.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
cancer  journal  liposarcoma  medworm sponsor  patients  sarcoma  sarcomas  soft tissue  soft  source  tissue  treatment  tumor 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Liposarcoma

MedWorm: Liposarcoma



MedWorm.com provides a medical RSS filtering service. Over 7000 RSS medical sources are combined and output via different filters. This feed contains the latest news and research in the Liposarcoma category.



Last Build Date: Mon, 28 Mar 2016 20:21:45 +0100

 



Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.

Mon, 28 Mar 2016 17:23:02 +0100

CONCLUSIONS: We demonstrated PIK3CA mutation and amplification in liposarcoma. PIK3CA copy number gain was an independent poor prognostic factor for DFS. Further studies are needed to evaluate the potential diagnostic and therapeutic role of PIK3CA mutations and amplifications in liposarcoma. PMID: 27016421 [PubMed - as supplied by publisher] (Source: Oncotarget)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Former Toronto Mayor Rob Ford's Rare Abdominal Cancer, Explained

Tue, 22 Mar 2016 22:18:35 +0100

Rob Ford, the controversial former Toronto mayor who was known both for smoking crack cocaine in office and his intense popularity among conservative working-class voters, died today at the age of 46. The cause of death was not announced, but Ford was being treated for rare abdominal cancer called pleomorphic liposarcoma -- a diagnosis he received in 2014.  "It's rare to have a highly successful outcome with a pleomorphic liposarcoma once it's spread," Dr. Brian Van Tine, a medical oncologist at Washington University in St. Louis, told the Canadian Press.  Liposarcomas belong to a class of tumors that begin in the body's connective tissue and resemble fat cells. They are relatively uncommon, only affecting about 2,000 people per year in the United States, according to Memori...



Rob Ford died suffering from pleomorphic liposarcoma

Tue, 22 Mar 2016 09:00:00 +0100

Former Toronto Mayor Rob Ford died Tuesday while suffering from a rare type of cancer known as pleomorphic liposarcoma. (Source: CBC | Health)



Liposarcoma masquerading as an inflammatory pseudotumor: a case report

Fri, 18 Mar 2016 00:00:00 +0100

Conclusion Taken together, our findings provide strong evidence that the original tumor was a misdiagnosed well-differentiated liposarcoma with extreme fibrosis, and the pleomorphic undifferentiated sarcoma represented a recurrence of the same tumor with dedifferentiation. (Source: Journal of Medical Case Reports)



Efficacy of neoadjuvant hypofractionated radiotherapy in patients with locally advanced myxoid liposarcoma

Fri, 18 Mar 2016 00:00:00 +0100

Conclusion Combined therapy with hypofractionated radiotherapy followed by immediate surgery seems to be effective therapy in MLPS demonstrating good local control and pathological response to therapy. (Source: European Journal of Surgical Oncology (EJSO))

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Regulatory mechanisms, expression levels and proliferation effects of the FUS–DDIT3 fusion oncogene in liposarcoma

Thu, 17 Mar 2016 00:00:00 +0100

Abstract Fusion oncogenes are among the most common types of oncogene in human cancers. The gene rearrangements result in new combinations of regulatory elements and functional protein domains. Here we studied a subgroup of sarcomas and leukaemias characterized by the FET (FUS, EWSR1, TAF15) family of fusion oncogenes, including FUS–DDIT3 in myxoid liposarcoma (MLS). We investigated the regulatory mechanisms, expression levels and effects of FUS–DDIT3 in detail. FUS–DDIT3 showed a lower expression than normal FUS at both the mRNA and protein levels, and single‐cell analysis revealed a lack of correlation between FUS–DDIT3 and FUS expression. FUS–DDIT3 transcription was regulated by the FUS promotor, while its mRNA stability depended on the DDIT3 sequence. FUS–DDIT3 protein st...



Neoadjuvant radiotherapy for retroperitoneal sarcoma: A systematic review

Wed, 16 Mar 2016 00:00:00 +0100

ConclusionsNART is a safe to use for RPS, but its effect toward survival and local control remains unclear. Without randomized control trials, common reporting criteria for pro‐ and retrospective studies are needed to allow comparison between studies. J. Surg. Oncol. © 2016 Wiley Periodicals, Inc. (Source: Journal of Surgical Oncology)



Escape from tumor dormancy and time to angiogenic switch as mitigated by tumor-induced stimulation of stroma

Mon, 14 Mar 2016 00:00:00 +0100

Publication date: 21 April 2016 Source:Journal of Theoretical Biology, Volume 395 Author(s): Irina Kareva A variety of mechanisms have been proposed to explain “cancer without disease”, the state of tumor dormancy, characterized by balance in cell proliferation and cell death within a tumor. Here we have investigated a theoretical construct, whereby one of such mechanisms, the time to induction of angiogenesis, or “angiogenic switch”, is mitigated by the degree of stromal stimulation by the tumor. We tested this hypothesis and its implications by introducing a mathematical model that captures how angiogenesis regulators, released from the platelet clot, contribute to formation of normal vasculature. We then modified the model to introduce tumor-induced increase in production of ...



The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study

Fri, 11 Mar 2016 00:00:00 +0100

CONCLUSIONSThere were apparent differences in the efficacy of pazopanib treatment among histologic types of STS. Pazopanib treatment is a new treatment option; however, adverse events like pneumothorax and thrombocytopenia, which did not occur frequently in the PALETTE study (pazopanib for metastatic soft‐tissue sarcoma), should be taken into consideration. Cancer 2016. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. (Source: Cancer)



Pharmaceutical Approval Update.

Thu, 10 Mar 2016 22:55:02 +0100

Authors: Fellner C Abstract Elbasvir/grazoprevir (Zepatier) for chronic hepatitis C virus; sumatriptin nasal powder (Onzetra Xsail) for migraine; eribulin mesylate (Halaven), now for liposarcoma; and extended-release amphetamine (Adzenys XR-ODT) for ADHD. PMID: 26957881 [PubMed] (Source: P and T)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Cutaneous Metastasis of Pleomorphic Liposarcoma to the Scalp: An elusive diagnosis

Thu, 10 Mar 2016 00:00:00 +0100

We present a patient with a known diagnosis of stage IV metastatic liposarcoma who presented to our clinic with a rapidly growing nodule on the scalp. A biopsy showed a high‐grade poorly differentiated spindled cell neoplasm sparing the epidermis with scattered lipoblasts. Immunostaining for S100, SOX10, and MNF‐116 were negative. To further characterize the neoplasm, immunostaining with MDM‐2 was performed and was also found to be negative. The histologic appearance, immunohistochemical staining, and clinical history support a diagnosis of metastatic pleomorphic liposarcoma to the scalp. The diagnosis of pleomorphic liposarcoma is challenging. It is often difficult to differentiate from myxofibrosarcoma or other high grade pleomorphic sarcomas based on histology alone. However, the ...



Managing Liposarcomas: Cutting Through the Fat [Clinical Reviews]

Wed, 09 Mar 2016 00:00:00 +0100

Liposarcomas are one of the most common of more than 50 histologic subtypes of soft tissue sarcomas that, themselves, are heterogeneous. Liposarcomas fall into four distinct histologic subtypes: atypical lipomatous tumor/well-differentiated liposarcoma, dedifferentiated liposarcoma, myxoid (round cell) liposarcoma, and pleomorphic liposarcoma. Definitive treatment remains surgical resection with negative margins for resectable disease. However, well-differentiated liposarcomas that are large or difficult to operate upon should be followed with close surveillance as long as there is no radiologic concern for a dedifferentiated component. In contrast, first-line chemotherapy with anthracycline with or without ifosfamide, or gemcitabine and docetaxel should be used for inoperable myxoid (roun...



Systemic Treatment of Liposarcomas: Light at the End of the Tunnel? [COMMENTARIES]

Wed, 09 Mar 2016 00:00:00 +0100

(Source: Journal of Oncology Practice)



New Approaches to Managing Liposarcoma: Will Cold Steel Remain the Only Way to Heal? [COMMENTARIES]

Wed, 09 Mar 2016 00:00:00 +0100

(Source: Journal of Oncology Practice)



FDA Approves Eribulin for Advanced Liposarcoma [News in Brief]

Sun, 06 Mar 2016 00:00:00 +0100

The FDA approved eribulin for treatment of advanced liposarcoma based on data from a phase III study showing that it increased overall survival by about 7 months compared with a commonly used chemotherapy, dacarbazine. (Source: Cancer Discovery)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




FDA Approves Halaven (Eribulin Mesylate) Injection for Liposarcoma

Thu, 03 Mar 2016 05:35:59 +0100

No abstract available (Source: Oncology Times)



Extra-adrenal myelolipoma presenting in the spleen: A report of two cases

Thu, 03 Mar 2016 00:00:00 +0100

We present two cases of myelolipoma in the spleen. The first is a 62year old female presenting with abdominal pain and a splenic mass. The second is a 44year old male presenting with hematuria and a mass in the spleen. Both cases showed trilineage bone marrow elements with mature fat. These cases demonstrate that myelolipoma do rarely occur in human spleen and we highlight the distinction from extramedullary hematopoiesis, mature extramedullary myeloid tumor (myeloid sarcoma), lipoma and well differentiated liposarcoma. Graphical abstract (Source: Human Pathology: Case Reports)



Liposarcoma of the cord treated with surgery alone: Our experience of five patients

Thu, 03 Mar 2016 00:00:00 +0100

Conclusion: Liposarcomas of the cord are rare soft-tissue sarcomas with a high incidence of recurrence. Treatment of choice is radical orchidectomy, wide excision of the tumour and high ligation of the spermatic cord. Long-term follow-up is necessary. (Source: Journal of Clinical Urology)



Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial [Rapid Communications]

Wed, 02 Mar 2016 00:00:00 +0100

Conclusion Trabectedin demonstrates superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma and leiomyosarcoma after they experience failure of prior chemotherapy. Because disease control in advanced sarcomas is a clinically relevant end point, this study supports the activity of trabectedin for patients with these malignancies. (Source: Journal of Clinical Oncology)



New Treatment for Liposarcoma

Tue, 01 Mar 2016 00:00:00 +0100

The chemotherapy drug eribulin mesylate has received approval for treating liposarcoma that is unresectable or has metastasized (http://1.usa.gov/1ZWmPRo). Marketed as Halaven, the drug is approved for patients previously treated with chemotherapy that contained an anthracycline drug. (Source: JAMA)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




The colorectal surgeon's liposarcoma

Tue, 01 Mar 2016 00:00:00 +0100

(Source: ANZ Journal of Surgery)



Intraoral Ultrasonography to Tongue Mass Lesions.

Mon, 29 Feb 2016 06:05:02 +0100

CONCLUSION: Intraoral ultrasonography of the tongue revealed the nature of the lesions including the border, size, location, depth, presence or absence of a capsule, and the internal structure including vascularity of the mass. The ultrasonographic findings well reflected the histological findings. IOUS is a simple and useful technique that provides additional information beyond inspection, clarifying the internal structure, blood flow, and relationships to the adjacent tissues. In this report, we indicated eleven representative cases compared to pathological findings (fibrous polyp, hemangioma, pyogenic granuloma, lipoma, liposarcoma, chondroma, lymphangioma, shwannoma, neurofibroma, pleomorphic adenoma, and amyloidosis) to indicate the usefulness of IOUS. PMID: 26915405 [PubMed - as ...



Lipoblastoma presenting as a rapidly growing paravertebral mass and masquerading as myxoid liposarcoma on fine needle aspiration cytology

Sat, 27 Feb 2016 08:20:06 +0100

We present here the case of a five‐ year old female child with a lipoblastoma presenting as a paravertebral mass in the right lower back which progressed rapidly in the previous six months causing diagnostic difficulty on fine needle aspiration cytology. Diagn. Cytopathol. 2016. © 2016 Wiley Periodicals, Inc. (Source: Diagnostic Cytopathology)



Cement leakage and complication of liposarcoma spinal metastasis during vertebral augmentation procedure: a case report

Wed, 24 Feb 2016 00:00:00 +0100

Conclusions The risk of cement leakage and embolism is increased with the treatment of some malignant lesions. The frequency of local leakage of bone cement is relatively high. Patients undergoing percutaneous vertebral augmentation of malignant spinal metastases need close monitoring. There is no agreement on the treatment strategy. (Source: Journal of Medical Case Reports)



Genotype–phenotype relationships in familial amyotrophic lateral sclerosis with FUS/TLS mutations in Japan

Tue, 23 Feb 2016 00:00:00 +0100

Conclusions: This study revealed a characteristic phenotype in FUS/TLS‐linked FALS patients in Japan. FUS/TLS screening is recommended in patients with FALS with this phenotype. Muscle Nerve, 2016 (Source: Muscle and Nerve)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b

Sun, 21 Feb 2016 00:00:00 +0100

Multiple sclerosis (MS) is the most common demyelinating diseases of central nervous system (CNS). Misdirected immune responses to CNS myelin antigens are considered pivotal in MS pathogenesis [1]. It is believed that interferon beta 1b (IFN-β-1b) is beneficial in the treatment of relapsing remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) as it has been shown in several clinical trials [2,3]. Even though it is assumed that the beneficial effect of IFN-β-1b is related to immunomodulation cells, the exact mechanisms of action of IFN-β-1b in MS remain unclear [4,5]. (Source: Journal of the Neurological Sciences)



Translocated in liposarcoma regulates the distribution and function of mammalian enabled, a modulator of actin dynamics

Sat, 20 Feb 2016 00:00:00 +0100

This article is protected by copyright. All rights reserved. (Source: FEBS Journal)



Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation

Sat, 20 Feb 2016 00:00:00 +0100

Conclusions Amrubicin has efficacy comparable to doxorubicin in adult STS, is well tolerated and has no significant cardiac toxicity up to a cumulative dose of 4800 mg /m2. Topoisomerase II inhibition with amrubicin warrants further study as a potential ‘targeted therapy’ for TLS-CHOP-translocated myxoid liposarcoma. Results from this trial favor the use of amrubicin for the treatment of STS. (Source: Investigational New Drugs)



MLN-8237; A dual inhibitor of aurora A and B in soft tissue sarcomas.

Fri, 19 Feb 2016 13:16:02 +0100

Authors: Nair JS, Schwartz GK Abstract Aurora kinases have become an attractive target in cancer therapy due to their deregulated expression in human tumors. Liposarcoma, a type of soft tissue sarcoma in adults, account for approximately 20% of all adult soft tissue sarcomas. There are no effective chemotherapies for majority of these tumors. Efforts made to define the molecular basis of liposarcomas lead to the finding that besides the amplifications of CDK4 and MDM2, Aurora Kinase A, also was shown to be overexpressed. Based on these as well as mathematic modeling, we have carried out a successful preclinical study using CDK4 and IGF1R inhibitors in liposarcoma. MLN8237 has been shown to be a potent and selective inhibitor of Aurora A. MLN-8237, as per our results, induces a diff...



Enhanced tumour regression in a patient of liposarcoma treated with radiotherapy and hyperthermia: Hint for dynamic immunomodulation by hyperthermia.

Thu, 18 Feb 2016 06:10:02 +0100

Authors: Datta NR, Grobholz R, Puric E, Bode-Lesniewska B, Lomax N, Khan S, Gaipl US, Fuchs B, Bodis S PMID: 25893831 [PubMed - in process] (Source: International Journal of Hyperthermia)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Lipomatous tumours of the face in infants: diagnosis and treatment.

Thu, 18 Feb 2016 04:08:02 +0100

CONCLUSIONS: The clinical presentation, histological features, imaging characteristics and treatment options are covered. It is suggested that a careful clinical examination is followed by magnetic resonance imaging. A histological analysis is often necessary to establish a definitive diagnosis, and a core needle biopsy is preferred in regards to sampling. Surgery is the treatment of choice, and should be performed by multidisciplinary teams in highly experienced centres. Individual surgical planning is mandatory. PMID: 25857338 [PubMed - as supplied by publisher] (Source: Journal of Plastic Surgery and Hand Surgery)



Neglected orthopedic oncology - Causes, epidemiology and challenges for management in developing countries

Thu, 18 Feb 2016 00:00:00 +0100

Conclusion: The current study tries to highlight the causes and quantity of neglect of malignant bone and soft tissue tumors prevalent in our country, which poses a therapeutic challenge for management and consequent mutilating surgeries with poor outcome resulting in loss of extremity and existence. (Source: Indian Journal of Cancer)



Carcinosarcoma of the upper urinary tract with an aggressive angiosarcoma component.

Thu, 18 Feb 2016 00:00:00 +0100

We report a case of a 44-year-old man with a localized right renal pelvis mass treated with a right nephroureterectomy. The pathological examination showed a high-grade urothelial carcinoma of the renal pelvis, stage III (pT3aNxM0). A few days later, he developed lower back pain, hematuria, cough with hemoptoic sputum and progressive dyspnea. Radiological explorations showed multiple bilateral lung nodules and a retroperitoneal mass. A CT-guided biopsy of the retroperitoneal mass revealed a high-grade angiosarcoma. A review of the nephrectomy specimen showed a microscopic focus of angiosarcoma in the urothelial carcinoma. Therefore, the initial diagnosis was changed to CS of the renal pelvis with an angiosarcoma component. The patient developed progressive respiratory failure and died eigh...



RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas.

Wed, 17 Feb 2016 15:28:02 +0100

Authors: Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Serra-Sitjar M, López-Guerrero JA, Ramos R, Alemany R, Martín-Broto J Abstract MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Selected sarcoma subtypes are being treated with Trabectedin in second line, which promotes DNA damage and p53-dependent apoptosis. The aim of this study was to evaluate the improvement of Trabectedin response with MDM2 inhibitors in soft tissue sarcomas. The antitumor effects of Trabectedin, Nutlin-3A and RG7112 as single agents or in combination were examined in vitro. RG7112 significantly synergized with Trabectedin in MDM2-amplified liposarcoma cells, representing a promising new therapeutic strategy for the treatment of sarcomas with MDM2 amplif...



RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas.

Wed, 17 Feb 2016 15:28:02 +0100

Authors: Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Serra-Sitjar M, López-Guerrero JA, Ramos R, Alemany R, Martín-Broto J Abstract MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Selected sarcoma subtypes are being treated with Trabectedin in second line, which promotes DNA damage and p53-dependent apoptosis. The aim of this study was to evaluate the improvement of Trabectedin response with MDM2 inhibitors in soft tissue sarcomas. The antitumor effects of Trabectedin, Nutlin-3A and RG7112 as single agents or in combination were examined in vitro. RG7112 significantly synergized with Trabectedin in MDM2-amplified liposarcoma cells, representing a promising new therapeutic strategy for the treatment of sarcomas with MDM2 amplif...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Profiling of potential driver mutations in sarcomas by targeted next generation sequencing

Wed, 17 Feb 2016 00:00:00 +0100

Publication date: Available online 15 February 2016 Source:Cancer Genetics Author(s): Carola Andersson, Henrik Fagman, Magnus Hansson, Fredrik Enlund Comprehensive genetic profiling by massively parallel sequencing, commonly known as next generation sequencing (NGS), is becoming the foundation of personalized oncology. For sarcomas very few targeted treatments are currently in routine use. In clinical practice the preoperative diagnostic workup of soft tissue tumors largely relies on core needle biopsies. Although mostly sufficient for histopathological diagnosis, only very limited amounts of formalin fixated paraffin embedded tissue is often available for predictive mutation analysis. Targeted NGS may thus open up new possibilities for comprehensive characterization of scarce biopsi...



Complete response of a recurrent-metastatic liposarcoma with dedifferentiated histological features following the administration of trabectedin and review of literature

Mon, 15 Feb 2016 00:00:00 +0100

In this study, trabectedin was used for the treatment of a metastatic retroperitoneal DDLS and a CR was achieved. (Source: Journal of Cancer Research and Therapeutics)



Liposarcoma of the maxillary antrum: A case report

Mon, 15 Feb 2016 00:00:00 +0100

We report a case of a 14-year-old girl diagnosed as ALT/WDL of the maxillary antrum. (Source: Journal of Cancer Research and Therapeutics)



Pleomorphic liposarcoma arising in a malignant phyllodes tumor of breast: A rare occurrence

Mon, 15 Feb 2016 00:00:00 +0100

Sankalp M Sancheti, Satyakam K Sawaimoon, Rosina AhmedJournal of Cancer Research and Therapeutics 2015 11(4):1032-1032Primary malignant phyllodes tumor of the breast accounts for 0.3-1% of all the tumors of breast and only a couple of cases of pleomorphic liposarcoma (PL) arising in a malignant phyllodes (MP) tumor have been reported. A thorough sampling is most essential in phyllodes tumor, not only to detect high grade component of the neoplasm but also to diagnose heterologous elements in the same lesion elsewhere, as it may affect the prognosis adversely and may have a greater metastatic potential. (Source: Journal of Cancer Research and Therapeutics)



Lipoblastoma and lipoblastomatosis: A clinicopathological study of six cases

Mon, 15 Feb 2016 00:00:00 +0100

Parul Ghosh, Ram Narayan Das, Ranajoy Ghosh, Uttara Chatterjee, Chhanda Datta, Prafulla Kumar MishraJournal of Cancer Research and Therapeutics 2015 11(4):1040-1040 Lipoblastoma and lipoblastomatosis are benign adipocytic tumors seen in children less than 3 years of age. Awareness amongst surgeons of this fast growing lipomatous tumor in young children is important to avoid mutilating surgery and chemotherapy. Histological diagnosis of lipoblastoma is sometimes difficult because of close resemblance with myxoid, round cell, and well-differentiated liposarcoma. We came across a series of six cases of lipoblastoma/lipoblastomatosis, over the last 10 years (2002–2012). Of these, we had three cases of lipoblastomatosis, one of which recurred after 2 months. All others were resect...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options.

Sun, 14 Feb 2016 14:15:02 +0100

Authors: Duffaud F, Maki RG, Jones RL Abstract Soft tissue sarcomas (STS) are rare mesenchymal cancers. Despite optimal management, nearly 50% of patients with localized disease will develop recurrence. The outcome for patients with metastatic STS is poor. There are few systemic treatment options available in this setting. Doxorubicin, with or without ifosfamide, is considered standard first line therapy. Some clinical trials have confirmed the activity of trabectedin as an effective and tolerable option for adult patients previously treated with doxorubicin and ifosfamide. Trabectedin was approved in the European Union and other countries based on the results of a randomized phase II trial involving patients with advanced liposarcoma and leiomyosarcoma receiving one of two differe...



Giant retroperitoneal paraspinal liposarcoma causing thoracolumbar scoliosis

Fri, 12 Feb 2016 00:00:00 +0100

An 82-year-old woman presented with left leg numbness and progressive weakness for 2 months. She had no history of trauma. Neurological examination revealed muscle power of grade 4/5 in the left leg. Spinal radiography revealed a thoracolumbar scoliosis (Fig. 1A) and L4–5 spondylolisthesis (Fig. 1B). However, a computed tomography scan revealed a giant retroperitoneal heterogeneous and poorly-enhanced mass (15.5 × 11.5 × 10.5cm) (Fig. 2A) with left vertebra compression (Fig. 2B) and extension into the left L4 and L5 neuroforamen (Fig. (Source: The Spine Journal)



Halaven (eribulin mesylate) for the Treatment of Advanced Liposarcoma

Thu, 11 Feb 2016 14:53:00 +0100

Halaven (eribulin mesylate) is an injectable chemotherapy drug developed by Eisai for the treatment of unresectable or metastatic liposarcoma patients that previously received anthracycline-based chemotherapy. (Source: Drug Development Technology)



Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Thu, 11 Feb 2016 00:00:00 +0100

Publication date: Available online 10 February 2016 Source:The Lancet Author(s): Patrick Schöffski, Sant Chawla, Robert G Maki, Antoine Italiano, Hans Gelderblom, Edwin Choy, Giovanni Grignani, Veridiana Camargo, Sebastian Bauer, Sun Young Rha, Jean-Yves Blay, Peter Hohenberger, David D'Adamo, Matthew Guo, Bartosz Chmielowski, Axel Le Cesne, George D Demetri, Shreyaskumar R Patel Background A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcoma. In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine (an active control). Methods We did this randomised, open-label, phase ...



Giant retroperitoneal liposarcoma: The silent tumour.

Wed, 10 Feb 2016 00:00:00 +0100

Authors: Galván Fernández J, Jiménez Cuenca MI, González Fuentes S, Benavides de la Rosa F PMID: 26874398 [PubMed - as supplied by publisher] (Source: Cirugia eEspanola)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




A well-differentiated mediastinal liposarcoma from the posterior mediastinum with separated solid and lipomatous regions: A case report

Tue, 09 Feb 2016 00:00:00 +0100

We report aninteresting case of a 74-year-old woman who underwent enhanced computed tomography that showed a heterogeneously enhancing solid mass with a large amount of fat involving the pleural and posterior mediastinum. (Source: The American Journal of Medicine)



Comprehensive genetic analysis of a paediatric pleomorphic myxoid liposarcoma reveals near‐haploidization and loss of the RB1 gene

Tue, 09 Feb 2016 00:00:00 +0100

ConclusionThe results support the notion that PML is a distinct type of liposarcoma, associated with a spectrum of somatic mutations that is different from that in other liposarcoma subtypes. The findings in the present case, combined with previous data, suggest that PML develops through combinations of numerical chromosome aberrations, possibly initialized by haploidization. The results also suggest that inactivation of RB1 is pathogenetically important. (Source: Histopathology)



Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma

Mon, 08 Feb 2016 22:20:25 +0100

Objective: To determine the prognostic significance of histologic type/subtype in a large series of patients with primary resected retroperitoneal sarcoma. Background: The histologic diversity and rarity of retroperitoneal sarcoma has hampered the ability to predict patient outcome. Methods: From a single-institution, prospective database, 675 patients treated surgically for primary, nonmetastatic retroperitoneal sarcoma during 1982 to 2010 were identified and histologic type/subtype was reviewed. Clinicopathologic variables were analyzed for association with disease-specific death (DSD), local recurrence (LR), and distant recurrence (DR). Results: Median follow-up for survivors was 7.5 years. The predominant histologies were well-differentiated liposarcoma, dedifferentiated liposarcoma...



Heterologous Liposarcomatous Differentiation in Malignant Phyllodes Tumor is Histologically Similar but Immunohistochemically and Molecularly Distinct from Well‐differentiated Liposarcoma of Soft Tissue

Thu, 04 Feb 2016 00:00:00 +0100

Abstract Malignant phyllodes tumor (PT) infrequently displays heterologous differentiation, and when present is most often liposarcomatous. We identified five cases of malignant PT with regions identical to well‐differentiated liposarcoma (WDLS) of soft tissue and evaluated them for MDM2 and CDK4 gene expression and amplification using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively. Despite indistinguishable morphology all cases of malignant PT with WDLS‐like liposarcomatous differentiation were negative for MDM2 and CDK4 IHC and FISH, supporting different underlying pathogenesis. (Source: The Breast Journal)



Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline

Tue, 02 Feb 2016 05:35:59 +0100

We report the long-term response to first-line trabectedin therapy in an elderly patient with metastatic leiomyosarcoma unfit for standard therapy. A 66-year-old woman underwent resection of a pelvic epithelioid leiomyosarcoma with positive margins in December 2002, followed by postoperative radiotherapy. In February 2012, she was diagnosed with multiple lung lesions and local relapse in the pelvis. As she was considered unsuitable for both anthracycline and ifosfamide because of cardiovascular comorbidities and because she was highly anxious at the prospect of developing alopecia, vomiting, and fatigue, we commenced treatment with trabectedin at 75% of the standard dose of 1.5 mg/m2 every 3 weeks. Treatment was well tolerated, and the patient continued treatment for 25 cycles, with dise...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Liposarcoma of thyroid gland: A review of the gained experience

Mon, 01 Feb 2016 00:00:00 +0100

Virad Kumar, Anoop Raj, Praveen Kumar RathoreIndian Journal of Cancer 2014 51(4):548-549 (Source: Indian Journal of Cancer)



Eisai’s Halaven Injection gets FDA approval to treat advanced liposarcoma

Mon, 01 Feb 2016 00:00:00 +0100

The US Food and Drug Administration (FDA) has granted approval for Eisai's Halaven (eribulin mesylate) Injection (0.5mg/mL) to treat patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. (Source: Pharmaceutical Technology)



Regulatory mechanisms, expression levels and proliferation effects of the FUS‐DDIT3 fusion oncogene in liposarcoma

Mon, 01 Feb 2016 00:00:00 +0100

Abstract Fusion oncogenes are one of the most common types of oncogenes in human cancers. The gene rearrangements result in new combinations of regulatory elements and functional protein domains. Here, we study a subgroup of sarcomas and leukaemias that is characterized by the FET (FUS, EWSR1, TAF15) family of fusion oncogenes, including FUS‐DDIT3 in myxoid liposarcoma. We investigated the regulatory mechanisms, expression levels and effects of FUS‐DDIT3 in detail. FUS‐DDIT3 showed a lower expression than normal FUS at both mRNA and protein levels, and single‐cell analysis revealed a lack of correlation between FUS‐DDIT3 and FUS expression. FUS‐DDIT3 transcription was regulated by the FUS promotor, while its mRNA stability depended on the DDIT3 sequence. FUS‐DDIT3 protein sta...



D.C. Week: Senator Places Hold on Califf's FDA Nomination

Sat, 30 Jan 2016 16:00:00 +0100

(MedPage Today) -- Breast cancer drug gains approval for liposarcoma (Source: MedPage Today Psychiatry)



FDA Approves Halaven (Eribulin) for Liposarcoma

Sat, 30 Jan 2016 03:39:18 +0100

By Stacy SimonThe US Food and Drug Administration (FDA) has approved the chemotherapy drug Halaven (eribulin) to treat liposarcoma, a type of soft tissue sarcoma. Halaven is already approved to treat advanced breast cancer. The new use is for people with liposarcoma who have already been treated with anthracycline-based chemotherapy and have tumors that cannot be removed through surgery or have spread to other parts of the body. This is the first drug approved for people with liposarcoma that has shown improvement in overall survival.Liposarcomas are cancerous tumors of fat tissue. They can develop anywhere in the body, but they most often develop in the thigh, behind the knee, and inside the back of the abdomen.The FDA based its approval on a clinical trial of 143 people with liposarcoma ...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




FDA Approves Eisai's Halaven(R) (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma

Fri, 29 Jan 2016 18:15:51 +0100

Halaven is the first and only single agent to prolong overall survival in patients with previously treated advanced (unresectable or metastatic) liposarcoma in a Phase 3 trial With these pivotal data, Halaven is twice-proven to give more time to patient... Biopharmaceuticals, Oncology, FDAEisai, Halaven, eribulin, Liposarcoma (Source: HSMN NewsFeed)



Halaven Approved for Advanced Soft Tissue Cancer

Fri, 29 Jan 2016 00:00:00 +0100

FDA says it's first liposarcoma drug to improve survival (Source: Cancercompass News: Other Cancer)



FDA Approves Halaven (eribulin mesylate) for the Treatment of Liposarcoma

Thu, 28 Jan 2016 20:01:47 +0100

January 28, 2016 -- The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable)... (Source: Drugs.com - New Drug Approvals)



Eribulin Approved for Liposarcoma, Improves SurvivalEribulin Approved for Liposarcoma, Improves Survival

Thu, 28 Jan 2016 19:24:07 +0100

Already approved for use in breast cancer, eribulin is the first drug to show an improved overall survival in patients with liposarcoma. News Alerts (Source: Medscape Medical News Headlines)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Breast Cancer Drug OK'd for Liposarcoma

Thu, 28 Jan 2016 19:09:39 +0100

(MedPage Today) -- Halaven is first agent to demonstrate survival benefit in rare cancer (Source: MedPage Today Primary Care)



FDA approves first drug to show survival benefit in liposarcoma

Thu, 28 Jan 2016 18:00:00 +0100

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. (Source: Food and Drug Administration)



Genotype–phenotype relationships in familial ALS with FUS/TLS mutations in Japan

Thu, 28 Jan 2016 00:00:00 +0100

Conclusions: This study revealed a characteristic phenotype in FUS/TLS‐linked FALS patients in Japan. FUS/TLS screening is recommended in patients with FALS with this phenotype. This article is protected by copyright. All rights reserved. (Source: Muscle and Nerve)



Primary liposarcoma of the sigmoid presenting as colonic intussusception - A case report.

Fri, 22 Jan 2016 07:19:03 +0100

We report a young patient with Crohn's disease in remission presenting with intussusception of the colon due to a primary liposarcoma of the sigmoid. Emergency resection confirmed the diagnosis. The patient remains in remission after five years. This represents the youngest diagnosis of liposarcoma to date and the first occurring in the sigmoid. We also highlight the concomitant diagnosis of Crohn´s disease. PMID: 26785977 [PubMed - as supplied by publisher] (Source: Revista Espanola de Enfermedades Digestivas)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




High diagnostic accuracy of core needle biopsy of soft tissue tumors: An institutional experience

Fri, 22 Jan 2016 00:00:00 +0100

ConclusionCNB is a reliable modality for evaluating soft tissue neoplasms, with high histologic concordance rate. Diagn. Cytopathol. 2016. © 2016 Wiley Periodicals, Inc. (Source: Diagnostic Cytopathology)



Cross-Sectional Imaging of Renal Masses: Image Interpretation Related Potential Pitfalls and Possible Solutions

Fri, 22 Jan 2016 00:00:00 +0100

After identifying and correcting pitfalls related to image acquisition, radiologists should focus their attention on the potential errors that can occur during image interpretation. Among them, the first and most important one is inappropriate characterization of a focus of normal renal tissue, congenital variant, or a benign infectious / inflammatory condition as a renal neoplasm on imaging studies.1 Secondly, identification of fat within a solid renal mass can create problems in distinguishing benign angiomyolipoma (AML) from malignant entities such as renal cell carcinoma (RCC), and liposarcoma. (Source: Seminars in Roentgenology)



Cross-Sectional Imaging of Renal Masses: Image Interpretation–Related Potential Pitfalls and Possible Solutions

Fri, 22 Jan 2016 00:00:00 +0100

After identifying and correcting pitfalls related to image acquisition, radiologists should focus their attention on the potential errors that can occur during image interpretation. Among them, the first and most important one is inappropriate characterization of a focus of normal renal tissue, congenital variant, or a benign infectious or inflammatory condition as a renal neoplasm on imaging studies.1 Secondly, identification of fat within a solid renal mass can create problems in distinguishing benign angiomyolipoma (AML) from malignant entities such as renal cell carcinoma (RCC) and liposarcoma. (Source: Seminars in Roentgenology)



Liposarcomatous differentiation in malignant phyllodes tumours is unassociated with MDM2 or CDK4 amplification

Tue, 19 Jan 2016 00:00:00 +0100

ConclusionsThis study examined molecular changes in the well‐differentiated liposarcomatous components of MPT. Despite histological similarity to well‐differentiated liposarcoma of soft tissues, liposarcomatous differentiation in MPT lacks the molecular phenotype characteristic of extramammary well‐differentiated liposarcoma. (Source: Histopathology)



Surgical management of spinal liposarcoma: a case series of 7 patients and literature review

Mon, 18 Jan 2016 00:00:00 +0100

Conclusion The outcome and prognosis of spinal liposarcoma is poor, and surgical resections should be considered when diagnosis is confirmed. For those whose tumors were too large to resect and/or with multiple metastases, effective treatment options are currently limited. Therefore, multidisciplinary treatment should be adopted, intraoperative chemotherapy, systemic chemotherapy and radiotherapy for instance. (Source: European Spine Journal)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Retroperitoneal Mass Presenting as Recurrent Inguinal Hernia: A Case Report

Sun, 17 Jan 2016 00:00:00 +0100

Publication date: Available online 14 January 2016 Source:International Journal of Surgery Case Reports Author(s): Ali Tardu, Mehmet Ali Yagci, Servet Karagul, Ismail Ertuğrul, Cuneyt Kayaalp Introduction: Retroperitoneal masses presenting as an inguinal hernia are rare conditions. Presentation of case: A 53 year old male admitted with the symptoms of weight loss, abdominal discomfort and left sided recurrent inguinal hernia. Physical examination demonstrated an abdominal mass in the left flank and an irreducible, painless scrotal mass. He had a history of left sided inguinal hernia surgery six years ago. Computed tomography revealed a large enhancing left sided retroperitoneal mass invading the colon, pancreas and kidney and it was going down towards the left scrotum. Unblock tumo...



Superficial liposarcoma: A retrospective review of 13 cases

Sat, 16 Jan 2016 05:16:33 +0100

To the Editor: Liposarcomas arising in the dermis or subcutaneous tissue are extremely rare and can be referred to as superficial liposarcomas.1 They can be divided into 3 types: atypical lipomatous tumor (well-differentiated and dedifferentiated types), myxoid, and pleomorphic.2-4 While high recurrence rates and metastases are well documented in liposarcomas of the deep soft tissue, less clinical and histopathologic information is available for the superficial form.5 We aimed to characterize the clinicohistopathologic features and evaluate outcomes of the superficial variant of liposarcoma. (Source: Journal of the American Academy of Dermatology)



Whole-body magnetic resonance imaging in myxoid liposarcoma: A useful adjunct for the detection of extra-pulmonary metastatic disease

Wed, 13 Jan 2016 00:00:00 +0100

Publication date: Available online 13 January 2016 Source:European Journal of Surgical Oncology (EJSO) Author(s): J.J. Watson, J.D. Stevenson, P. Cool, G.L. Cribb, J.P.R. Jenkins, M. Leahy, J.J. Gregory Myxoid liposarcomas (MLS) are a subgroup of soft-tissue sarcomas which have a propensity for extra-pulmonary metastases. Conventional radiological staging of soft-tissue sarcomas consists of chest radiographs (CXR) and thoracic computed tomography (CT) for possible chest metastases, supplemented by magnetic resonance imaging (MRI) for local disease. The optimal radiological modality to detect extra-pulmonary metastases for systemic staging has not been proven. We reviewed the efficacy of Whole-Body MRI (WBMRI) for this purpose. 33 WBMRI and simultaneous CT scans were performed in 2...



Abstract A14: Molecular fidelity of patient derived xenograft (PDX) models to original human tumor and to the cancer genome atlas (TCGA)

Thu, 07 Jan 2016 00:00:00 +0100

ConclusionDetailed comparison of several PDX models to the human tumor counterpart demonstrated high fidelity, not only at the gene level but also the mutation and CNA level. Cohort comparisons were correlative as well, but a certain bias was discerned in both MC and SMG analyses. There could be several causes for this, including statistical artifacts due to small cohort sizes, clinical and demographic differences between the Champions and TCGA patient profiles, or biological factors such as clonal selection and engraftment pressure. Further analysis is ongoing to better understand the model at a molecular level and maximize its utility as a robust translational research tool.Citation Format: Ido Ben-Zvi, Ido Sloma, Tin Khor, Daniel Ciznadija, Amanda Katz, David Vasquez, David Sidransky, K...



Abstract B27: A phase I dose escalation study of the MDM2 inhibitor DS-3032b in patients with advanced solid tumors and lymphomas

Thu, 07 Jan 2016 00:00:00 +0100

Conclusions: DS-3032b shows an acceptable safety profile at the tRP2D of 120mg QD x 21/28. Preliminary evidence of clinical activity with prolonged PFS was seen in WD/DD LPS in which MDM2 is universally amplified, warranting further investigation in this disease. ClinicalTrials.gov Identifier: NCT01877382Citation Format: Todd Bauer, David Hong, Neeta Somaiah, Charles Cai, Saeheum Song, Prasanna Kumar, Roohi Gajee, Michael Rosen, Jarema Kochan, Shuquan Chen, David Hyman, Tyler Masters, Funda Meric-Bernstam, Archie Tse, Patricia LoRusso, Amy Weise, Mrinal Gounder. A phase I dose escalation study of the MDM2 inhibitor DS-3032b in patients with advanced solid tumors and lymphomas. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeut...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Abstract B30: A phase 1 open label, dose-escalation trial evaluating the safety and tolerability of EF-022, macrophage activator, in subjects with advanced solid malignancies

Thu, 07 Jan 2016 00:00:00 +0100

Conclusions: Treatment with EF-022 has an acceptable safety profile and resulted in disease stabilization in 42% of patients. Pharmacodynamics markers suggest a reduction of Tregs and increase of the M1/M2 ratio. These findings are being further explored in a dose expansion cohort.ClinicalTrials.gov Identifier: NCT02052492Citation Format: Talia Golan, Raanan Berger, Aliza Ackerstein, Steve Raskin, Alexander M. Lesokhin, David Sidransky, Mark L. Levitt, Hana Gadassi, Uri Yogev, Michal Shahar. A phase 1 open label, dose-escalation trial evaluating the safety and tolerability of EF-022, macrophage activator, in subjects with advanced solid malignancies. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, ...



Langerhans cell sarcoma of the head and neck

Sat, 02 Jan 2016 00:00:00 +0100

Head and neck (HN) sarcomas constitute a rare heterogeneous group of cancers that arise from the soft tissue or bony component of this region. These tumors account for less than 1% of all head and neck malignancies and carry a relatively poor prognosis as compared to their counterparts at other sites. Rhabdomyosarcoma is the commonest head and neck soft tissue sarcoma in both the adult and paediatric population; the other common sarcomas being angiosarcoma, dermatofibrosarcoma, liposarcoma, ewings sarcoma and osteosarcoma (O’Sullivan and Gullane, 2009). (Source: Critical Reviews in Oncology Hematology)



Sclerosing liposarcoma of the anterior mediastinum: An unusual case.

Fri, 01 Jan 2016 00:00:00 +0100

Authors: Arava S, Breta M, Madan K, Nath D, Mehta S, Jain D Abstract Liposarcomas are extremely rare in the mediastinum. Patients usually present late due to the compressive effect of the tumor on the adjacent structures. Severity of the symptoms depend mainly on the size of the tumor and the structure it infiltrates. Well differentiated slow growing liposarcomas are the most common ones in the mediastinum followed by dedifferentiated and poorly differentiated ones. These tumors have bad prognosis because of incomplete surgical excision due to its inaccessible location. Hence these patients should be kept under close follow up because of high recurrent rates. Here we are presenting a rare case of anterior mediastinal sclerosing liposarcoma in a 77 year old male. PMID: 26960640...



Cyclin-dependent kinase pathways as targets for women's cancer treatment

Wed, 23 Dec 2015 21:00:16 +0100

Purpose of review: In this article, we not only review the preclinical and clinical studies of cyclin-dependent kinase (CDK) 4/6 inhibitors in breast cancer, liposarcoma, mantel cell lymphoma, melanoma and germ cell tumors, but also examine promising preclinical data in glioblastoma, renal and ovarian cancer models that may provide directions for future development. Recent findings: Targeting CDKs has been the focus of considerable basic science and clinical research. The CDK 4/6 inhibitors are a novel class of therapeutics that target the CDK 4/6 kinases that promote transition through the cell cycle. Currently, palbociclib (PD0332991, Pfizer), abemaciclib (LY2835219, Lilly) and ribociclib (LEE011, Novartis) are being investigated in clinical trials. These oral agents offer the hope of cl...



Histopathological Spectrum of Tumor and 
Tumor-like Lesions of the Paratestis in a 
Tertiary Care Hospital.

Sat, 19 Dec 2015 05:05:58 +0100

CONCLUSION: Neoplasms of the paratesticular region affect patients of all ages, with potentially life-threatening sequelae. Awareness of the entire spectrum and meticulous histopathological examination and immunohistochemical studies are of prime importance in the diagnosis of the various lesions as these influence the mode of therapy and subsequent prognosis of the patient. PMID: 26674546 [PubMed] (Source: Oman Medical Journal)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Paratesticular liposarcoma of the spermatic cord: a case report and review of the literature.

Tue, 15 Dec 2015 21:38:02 +0100

In conclusion, spermatic cord liposarcoma are rare neoplasm that present as firm, slow-growing palpable paratesticular masses and the surgical treatment should include a wide resection around the inguinal canal, with removal of the spermatic cord and the surrounding soft tissue deep to the internal inguinal ring. PMID: 26662152 [PubMed - as supplied by publisher] (Source: Romanian Journal of Morphology and Embryology)



The emerging roles and therapeutic potential of microRNAs (miRs) in liposarcoma.

Sun, 13 Dec 2015 15:58:02 +0100

Authors: Sun R, Shen JK, Choy E, Yu Z, Hornicek FJ, Duan Z Abstract Liposarcoma (LPS) is a common subtype of soft tissue sarcoma and accounts for approximately 20% of adult sarcomas. Despite the progress in diagnosis and treatment of LPS, there is still a high mortality rate due to local recurrence or metastasis. The mechanisms underlying the development of recurrence and metastasis of LPS remain elusive. MicroRNAs (miRNAs or miRs) are non-coding RNAs that regulate target gene expression, influencing many cellular functions, including cell proliferation, apoptosis, differentiation, oncogenesis, and drug resistance in malignant cells. The dysregulation of miRs is involved in the initiation and progression of human cancers, including LPS. Functional studies have shown the potent pro-...



Genomic landscape of liposarcoma.

Fri, 11 Dec 2015 12:08:05 +0100

Authors: Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Myklebost O, Yang H, Dugas M, Meza-Zepeda LA, Silberman AW, Forscher C, Tyner JW, Ogawa S, Koeffler HP Abstract Liposarcoma (LPS) is the most common type of soft tissue sarcoma accounting for 20% of all adult sarcomas. Due to absence of clinically effective treatment options in inoperable situations and resistance to chemotherapeutics, a critical need exists to identify novel therapeutic targets. We analyzed LPS genomic landscape using SNP arrays, whole exome sequencing and targeted exome sequencing to uncover the genomic information for development of specific anti-cancer targets....



Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies

Wed, 09 Dec 2015 20:14:19 +0100

Well-differentiated liposarcoma (WDL) and dedifferentiated liposarcoma (DDL) form the largest subgroup of liposarcomas, and represent a morphologic and behavioral spectrum of 1 disease entity, which arises typically in middle to late adult life, most frequently within the retroperitoneum or extremities. DDL is defined as nonlipogenic sarcoma that is juxtaposed to WDL, occurs as a recurrence of WDL or which can arise de novo, and typically has the appearance of undifferentiated pleomorphic or spindle cell sarcoma. DDL have a propensity for local recurrence, whereas distant metastasis is rarer, and behavior is related to anatomic site, with retroperitoneal neoplasms showing a significantly worse prognosis. Surgical resection remains the mainstay of treatment, and medical options for patients...



Comprehensive genetic analysis of a pediatric pleomorphic myxoid liposarcoma reveals near‐haploidization and loss of the RB1 gene

Wed, 09 Dec 2015 00:00:00 +0100

ConclusionThe results support the notion that PML is a distinct type of liposarcoma, associated with a spectrum of somatic mutations that is different from that in other liposarcoma subtypes. The findings in the present case, combined with previous data, suggest that PML develops through combinations of numerical chromosome aberrations, possibly initialized by haploidization. The results also suggest that inactivation of RB1 is pathogenetically important.This article is protected by copyright. All rights reserved. (Source: Histopathology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Lipophyllodes Of The Breast. A Reappraisal Of Fat-Rich Tumors Of The Breast Based On 22 Cases Integrated By Immunohistochemical Study, Molecular Pathology Insights And Clinical Follow Up

Wed, 09 Dec 2015 00:00:00 +0100

We have studied 22 cases of mammary lipophyllodes tumors (LPT), analyzing their clinicopathologic features along with available follow-up. All cases were tested for cytokeratins, S100 protein, MDM2, and in selected cases for ER, smooth muscle actin, bcl2, desmin and myogenin. Patients were females, 21–69 years of age, average 45 years; LPT size range was 1.6–30 cm, average 9.7 cm. Microscopically, LPT segregated as follows: atypical lipoma-like tumor/well differentiated liposarcoma (ALT/WDL), 8 cases; myxoid, 6; pleomorphic/poorly differentiated/round cell, 8, including a case of dedifferentiated liposarcoma. (Source: Annals of Diagnostic Pathology)



Targeting Protein Kinases to Reverse Multidrug Resistance in Sarcoma

Tue, 08 Dec 2015 00:00:00 +0100

Sarcomas are a heterogenous group of malignant tumors that arise from transformed cells of mesenchymal origin. Sarcomas are divided into two main groups: soft tissue sarcomas and bone sarcomas. Soft tissue sarcomas (STS) originate in connective tissues such as fat, muscle, nerve, tendon, the lining of joints, blood vessels, or lymph vessels. There are more than 50 different histological subtypes of STS, such as undifferentiated pleomorphic sarcoma (UPS), rhabdomyosarcoma, liposarcoma, angiosarcoma, synovial sarcoma, leiomyosarcoma, and others. (Source: Cancer Treatment Reviews)



[In Process Citation].

Mon, 30 Nov 2015 22:04:02 +0100

Authors: Bassetti R, Tomasetti P, Kuttenberger J Abstract Lipomas represent a relatively rare finding in the oral cavity. They are classed with soft tissue mesenchymal neoplasms, are benign and normally show a painless slow-growing character. Important is the differential diagnosis toward the liposarcomas, which represent a malignant version of adipose neoplasia and as well show a painless slow-growing character. Therefore, in case of clinical suspicion of a lipoma, a histopathological examination of the excisional biopsy has to be exercised in order to confirm the clinical diagnosis. The aim of the present case report is to present the step-by-step procedure of a lipoma excision at the base of the tongue and to give an overview of the literature. PMID: 26179451 [PubMed - in p...



Recurrent lipomatous tumor of hypopharynx: case report and literature review.

Mon, 30 Nov 2015 21:58:02 +0100

We present an unusual case of well-differentiated liposarcoma of the hypopharynx in a patient with previous three procedures of endoscopic removal of hypopharyngeal tumor classified as benign lipoma. Well-differentiated liposarcoma is a tumor of low-grade malignancy, which frequently recurs locally, but does not metastasize. Wide tumor resection with free margins is mandatory. Immunohistochemistry is a useful diagnostic tool. We also discuss recently published literature on this unusual presentation of well-differentiated liposarcoma. PMID: 25509250 [PubMed - indexed for MEDLINE] (Source: Acta Clinica Croatica)



Primary orbital liposarcoma: A case report.

Sat, 28 Nov 2015 12:51:34 +0100

Authors: Chebbi A, Hachicha F, Ben Hssine L, Feki O, Bouayed E, Malek I, Zeghal I, Bellagha I, Bouguila H, Nacef L PMID: 26563839 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.

Thu, 26 Nov 2015 11:18:03 +0100

Authors: Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stenman G, Stock RS, Ståhlberg A, Åman P Abstract Myxoid sarcoma (MLS) is one of the most common types of malignant soft tissue tumors. MLS is characterized by the FUS-DDIT3 or EWSR1-DDIT3 fusion oncogenes that encode abnormal transcription factors. The receptor tyrosine kinase (RTK) encoding RET was previously identified as a putative downstream target gene to FUS-DDIT3 and here we show that cultured MLS cells expressed phosphorylated RET together with its ligand Persephin. Treatment with RET specific kinase inhibitor Vandetanib failed to reduce RET phosphorylation and inhibit cell growth, suggest...



Treatment with a Global Methyltransferase Inhibitor Induces the Intranuclear Aggregation of ALS-Linked FUS Mutant In Vitro.

Tue, 24 Nov 2015 00:00:00 +0100

Authors: Fujii S, Takanashi K, Kitajo K, Yamaguchi A Abstract FUS/TLS (fused in sarcoma/translocated in liposarcoma) encodes a multifunctional DNA/RNA binding protein with non-classical carboxy (C)-terminal nuclear localization signal (NLS). A variety of ALS-linked mutations are clustered in the C-terminal NLS, resulting in the cytoplasmic mislocalization and aggregation. Since the arginine methylations are implicated in the nuclear-cytoplasmic shuttling of FUS, a methylation inhibitor could be one of therapeutic targets for FUS-linked ALS. We here examined effects of methylation inhibitors on the cytoplasmic mislocalization and aggregates of ALS-linked C-terminal FUS mutant in a cell culture system. Treatment with adenosine dialdehyde (AdOx), a representative global methyltransfer...



Chondroitin sulfate synthase-1 expression is associated with malignant potential of soft tissue sarcomas with myxoid substance

Sat, 21 Nov 2015 00:00:00 +0100

The glycosyltransferases chondroitin sulfate synthase-1 (CHSY1) and exostoses-like 3 (EXTL3) specifically function in biosynthesis of the glycans chondroitin sulfate (CS) and heparan sulfate (HS), respectively. Although these glycans play important roles in pathogenesis of various tumors, their significance in soft tissue sarcoma remains unknown. Here, we asked whether CHSY1 or EXTL3 expression correlates with malignant potential of soft tissue sarcomas with myxoid substance. To do so, we examined 40 samples representing specific types, including 12 cases of myxoid liposarcoma, 14 of myxofibrosarcoma (MFS), 12 of malignant peripheral nerve sheath tumor (MPNST), and 2 of low-grade fibromyxoid sarcoma. (Source: Human Pathology)



Chondroitin sulfate synthase 1 expression is associated with malignant potential of soft tissue sarcomas with myxoid substance

Sat, 21 Nov 2015 00:00:00 +0100

The glycosyltransferases chondroitin sulfate synthase 1 (CHSY1) and exostoses-like 3 (EXTL3) specifically function in biosynthesis of the glycans chondroitin sulfate and heparan sulfate, respectively. Although these glycans play important roles in pathogenesis of various tumors, their significance in soft tissue sarcoma remains unknown. Here, we asked whether CHSY1 or EXTL3 expression correlates with malignant potential of soft tissue sarcomas with myxoid substance. To do so, we examined 40 samples representing specific types, including 12 cases of myxoid liposarcoma, 14 of myxofibrosarcoma, 12 of malignant peripheral nerve sheath tumor, and 2 of low-grade fibromyxoid sarcoma. (Source: Human Pathology)



A novel surgical approach for the treatment of tumors in the lesser trochanter.

Wed, 18 Nov 2015 20:17:51 +0100

Authors: Yu Y, Sun X, Song X, Tian Z, Zhou Y Abstract The proximal femur is a common location for the development of primary benign bone tumors. However, there is currently no surgical technique designed specifically for treating tumors located in the lesser trochanter. In the present study, a novel procedure was developed for directly exposing the lesser trochanter for surgical intervention. This technique may be particularly suited to treating tumors that extend toward the lateral and anterior forward of the lesser trochanter. The new approach involved passing through the femoral triangle, separating the femoral nerve and femoral vessels (artery and vein) and resecting the tumor between the iliopsoas and pectineal muscles. The procedure was performed on six patients with various ...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Limb-sparing surgery as an alternative for limb amputation in an invasive myxoid liposarcoma--case report.

Wed, 18 Nov 2015 20:14:32 +0100

Authors: Adameșteanu MO, Enache V, Zamfirescu D, Lascăr I Abstract In medical practice, plastic surgeons confront with patients with sarcomas of the extremities that require a radical surgical approach. Knowing when to attempt limb-sparing surgery and when to give in to limb amputation is one of the most difficult decisions a surgeon can take. The correct approach and management of such cases ensure surgical success and the patient survival. In this paper, the case of a 56-year-old man, admitted in our clinic with a crush injury of the right calf and subsequent haematoma is presented. During haematoma drainage, the surgeon noticed abnormal tissue and performed an incisional biopsy. The patient was diagnosed with myxoid liposarcoma of the external compartment of the right calf. Li...



Hyperthermia increases natural killer cell cytotoxicity against SW-872 liposarcoma cell line.

Wed, 18 Nov 2015 13:16:25 +0100

CONCLUSION: The observed increase in the cytotoxicity of NK cells against SW-872 cells after hyperthermia does not coincide with changes in MICA/B, ULBP1 and ULBP2 ligands of NKG2, however, the expression of other ligands in target cells may have made the cells susceptible to the cytotoxic effect of NK cells. PMID: 23811548 [PubMed - indexed for MEDLINE] (Source: Iranian Journal of Immunology)



Effect of thermal stress on MICA/B induction in a human liposarcoma cell line.

Wed, 18 Nov 2015 13:16:25 +0100

CONCLUSION: Our data conclude that thermotherapy under 42-46 C had no effect on MICA/B induction on SW-872 liposarcoma cell line but the effects of fever-range temperatures remain to be tested on this cell line. PMID: 23502336 [PubMed - indexed for MEDLINE] (Source: Iranian Journal of Immunology)



Abstract A2-20: Integrative study of genomic alterations in liposarcoma

Sun, 15 Nov 2015 00:00:00 +0100

Liposarcoma (LPS) is the most common type of soft tissue sarcoma and accounts for approximately 20% of all adult sarcomas. Due to absence of clinically effective treatment options with a high rate of recurrence and resistance to conventional therapeutics agent, a critical need exists to identify the therapeutic targets for treating this deadly disease. Our study aims to further understanding of LPS pathobiology by constructing a detailed genetic and molecular landscape of LPS through a series of integrated comprehensive genomic and transcriptomic analysis.We performed SNP CHIP array analysis on 92 LPS cases and 13 LPS cell lines, whole-exome sequencing analysis of 12 LPS-normal paired samples, transcriptome sequencing of 5 cases, targeted whole-exome sequencing of 86 LPS cases and 13 LPS c...



AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas

Sat, 14 Nov 2015 00:00:00 +0100

Conclusions: Our results suggest that AXL signaling contributes to the aggressiveness of DDLPS and PLS, and that AXL is therefore a potential therapeutic target for treatment of these rare, yet devastating tumors. (Source: BMC Cancer)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Lipomatous angiomyofibroblastoma of the vulva: diagnostic and histogenetic considerations.

Fri, 13 Nov 2015 09:40:03 +0100

We report a rare case of angiomyofibroblastoma (AMFB) of the vulva, composed predominantly of a mature fatty component, representing approximately 60% of the entire tumour. The tumour, designated as "lipomatous AMFB", should be interpreted as the morphological result of an unbalanced bidirectional differentiation of the presumptive precursor stromal cell resident in the hormonally-responsive stroma of the lower genital tract, with the adipocytic component overwhelming the fibroblastic/myofibroblastic one. The close admixture of adipocytes with spindled/epithelioid cells of the conventional AMFB resulted, focally, in a pseudo-infiltrative growth pattern and pseudo-lipoblast-like appearance, raising problems in differential diagnosis, especially with well-differentiated lipoma-like liposarco...



Giant Gastric Liposarcoma: A Fatal Exceptional Location

Wed, 11 Nov 2015 00:00:00 +0100

(Source: Journal of Gastrointestinal Cancer)